Congressional Budget Office and Government Accountability Office analysis

Not later than 90 days after the completion of the release of agreements listed under section 2(a)(2), the Director of the Congressional Budget Office and the Comptroller General of the United States, jointly, shall publish a report on the economic and budgetary effects of all agreements disclosed under section 2, including— (1) the expected economic and budgetary consequences of each such agreement; (2) an analysis of direct cost savings that individuals in the United States have received and can expect to receive, by insurance status, including uninsured individuals, as a consequence of the agreements; (3) a budget analysis of the impacts of the agreements on the Medicare program under title XVIII of the Social Security Act (42 U.S.C. 1395 et seq.), the Medicaid program under title XIX of such Act (42 U.S.C. 1396 et seq.), and qualified health plans offered through the American Health Benefit Exchanges established under section 1311 or 1321 of the Patient Protection and Affordable Care Act (42 U.S.C. 18031; 18041); and (4) any impact, or expected impact, on— (A) drug price competition (such as through shifts from the use of generic drugs to brand name drugs); (B) section 1128B of the Social Security Act (commonly referred to as the Federal Anti-Kickback Statute (42 U.S.C. 1320a–7b)); and (C) health plan formulary design (such as cost shifting, adverse events for health plans, and spending acceleration).